Psychopharmacology of violence. Part II: Beyond the acute episode

Psychiatric Annals

Volumn 27, Issue 10, 1997, Pages 696-703

  Citrome, Leslie ^a,b   Volavka, Jan ^a  

^a NEW YORK UNIVERSITY   (United States)

^b NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 7244251770     PISSN: 00485713     EISSN: None     Source Type: Journal    
DOI: 10.3928/0048-5713-19971001-11     Document Type: Article

References (97)

1. Volavka J. Neurobiology of Violence. Washington, DC: American Psychiatric Press, Inc; 1995.
2. Krakowski MI, Kunz M, Czobor P, Volavka J. Long-term high-dose neuroleptic treatment: who gets it and why? Hosp Community Psychiatry. 1993; 44:640-644.
3. Apter A, Van Praag HM, Plutchik R, Sevy S, Korn M, Brown SL. Interrelationships among anxiety, aggression, impulsivity, and mood: a serotonergically linked cluster? Psychiatr Res. 1990; 32:191-199.
4. Roy A, Linnoila M. Suicidal behavior, impulsiveness and serotonin. Acta Psychiatr Scand. 1988; 78:529-535.
5. Virkkunen M, Goldman D, Nielsen DA, Linnoila M. Low brain serotonin turnover rate (low CSF 5-HIAA) and impulsive violence. J Psychiatry Neurosci. 1995; 20:271-275.
6. Linnoila M, Virkkunen M, Scheinin M, Nuutila A, Rimon R, Goodwin FK. Low cerebrospinal fluid 5-hydroxyindole acetic acid concentration differentiates impulsive from non-impulsive violent behavior. Life Sci. 1983; 33:2609-2614.
7. Virkkunen M, Linnoila M. Serotonin in early onset, male alcoholics with violent behavior. Ann Med. 1990; 22:327-331.
8. Virkkunen M, De Jong J, Bartko J, Linnoila M. Psychobiological concomitants of history of suicide attempts among violent offenders and impulsive fire setters. Arch Gen Psychiatry. 1989; 46:604-606.
9. Coccaro EF, Siever LJ, Mar HM, et al. Serotonergic studies in patients with affective and personality disorders. Arch Gen Psychiatry. 1989; 46:587-599.
10. Wilson WH, Claussen AM. 18-month outcome of clozapine treatment for 100 patients in a state psychiatric hospital. Psychiatr Serv. 1995; 46:386-389.
11. Ratey JJ, Leveroni C, Kilmer D, Gutheil C, Swartz B. The effects of clozapine on severely aggressive psychiatric inpatients in a state hospital. J Clin Psychiatry. 1993; 54:219-223.
12. Michals ML, Crismon ML, Roberts S, et al. Clozapine response and adverse effects in nine brain-injured patients. J Clin Psychopharmacol. 1993; 13:198-203.
13. Volavka J, Zito JM, Vitrai J, Czobor P. Clozapine effects on hostility and aggression in schizophrenia. J Clin Psychopharmacol. 1993; 13:287-289.
14. Chiles JA, Davidson P, McBride D. Effects of clozapine on use of seclusion and restraint at a state hospital. Hosp Community Psychiatry. 1994; 45:269-271.
15. Czobor P, Volavka J, Meibach RC. Effect of risperidone on hostility in schizophrenia. J Clin Psychopharmacol. 1995; 15:243-249.
16. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry. 1994; 151:825-835.
17. Williams DT, Mehl R, Yudofsky S, et al. The effect of propranolol on uncontrolled rage outbursts in children and adolescents with organic brain dysfunction. Am Acad Child Psychiatry. 1982; 21:129-135.
18. Petrie WM, Ban TA. Propranolol in organic agitation. Lancet. 1981; 1:324. Letter.
19. Ratey JJ, Mikkelsen EJ, Smith GB, et al. Beta-blockers in the severely and profoundly mentally retarded. J Clin Psychopharmacol. 1986; 6:103-107.
20. Ratey JJ, Morrill R, Oxenkrug G. Use of propranolol for provoked and unprovoked episodes of rage. Am J Psychiatry. 1983; 140:1356-1357.
21. Ratey JJ, Mikkelsen E, Sorgi P, et al. Autism: the treatment of aggressive behaviors. J Clin Psychopharmacol. 1987; 7:35-41.
22. Elliott FA. Propranolol for the control of belligerent behavior following acute brain damage. Ann Neurol. 1977; 1:489-491.
23. Yudofsky S, Williams D, Gorman J. Propranolol in the treatment of rage and violent behavior in patients with chronic brain syndrome. Am J Psychiatry. 1981; 138:218-220.
24. Mansheim P. Treatment with propranolol of the behavioral sequelae of brain damage. J Clin Psychiatry. 1981; 42:132. Letter.
25. Yudofsky SC, Stevens L, Silver JM, Barsa J, Williams D. Propranolol in the treatment of rage and violent behavior associated with Korsakoff's psychosis. Am J Psychiatry. 1984; 141:114-115.
26. Greendyke RM, Kanter DR, Schuster DB, et al. Propranolol treatment of assaultive patients with organic brain disease. J Nerv Ment Dis. 1986; 174:290-294.
27. Stewart JT, Mounts ML, Clark RL Jr. Aggressive behavior in Huntington's disease: treatment with propranolol. J Clin Psychiatry. 1987; 48:106-108.
28. Schreier HA. Use of propranolol in the treatment of postencephalitic psychosis. Am J Psychiatry. 1979; 156:840-841.
29. Yudofsky SC, Silver JM, Hales RE. Pharmacologic management of aggression in the elderly. J Clin Psychiatry. 1990; 51(suppl):22-28.
30. Sheppard GP. High-dose propranolol in schizophrenia. Br J Psychiatry. 1979; 134:470-476.
31. Sorgi PJ, Ratey JJ, Polakoff S. Beta-adrenergic blockers for the control of aggressive behaviors in patients with chronic schizophrenia. Am J Psychiatry. 1986; 143:775-776.
32. Ratey JJ, Sorgi P, O'Driscoll GA, et al. Nadolol to treat aggression and psychiatric symptomatology in chronic psychiatric inpatients: a double-blind, placebo-controlled study. J Clin Psychiatry. 1992; 53:41-46.
33. Alpert M, Allan ER, Citrome L, Laury G, Sison C, Sudilovsky A. A double-blind, placebo-controlled study of adjunctive nadolol in the management of violent psychiatric patients. Psychopharmacol Bull. 1990; 26:367-371.
34. Polakoff SA, Sorgi PJ, Ratey JJ. The treatment of impulsive and aggressive behavior with nadolol. J Clin Psychopharmacol. 1986; 6:125-126. Letter.
35. Mattes JA. Metoprolol for intermittent explosive disorder. Am J Psychiatry. 1985; 142:1108-1109.
36. Kastner T, Burlingham K, Friedman DL. Metoprolol for aggressive behavior in persons with mental retardation. Am Fam Physician. 1990; 42:1585-1588.
37. Greendyke RM, Kanter DR. Therapeutic effects of pindolol on behavioral disturbances associated with organic brain disease: a double-blind study. J Clin Psychiatry. 1986; 47:423-426.
38. Citrome L. Use of lithium, carbamazepine, and valproic acid in a state-operated psychiatric hospital. Journal of Pharmacy Technology. 1995; 11:55-59.
39. Yesavage JA. Bipolar illness: correlates of dangerous inpatient behavior. Br J Psychiatry. 1983; 143:554-557.
40. Dostal T, Zvolsky P. Antiaggressive effect of lithium salts . in severe mentally retarded adolescents. International Pharmacopsychiatry. 1970; 5:203-207.
41. Tyrer SP, Walsh A, Edwards DE, et al. Factors associated with a good response to lithium in aggressive mentally handicapped subjects. Prog Neuropsychopharmacol Biol Psychiatry. 1984; 8:751-755.
42. Spreat S, Behar D, Reneski B, et al. Lithium carbonate for aggression in mentally retarded persons. Compr Psychiatry. 1989; 30:505-511.
43. Craft M, Ismail IA, Krishnamurti D, et al. Lithium in the treatment of aggression in mentally handicapped patients. A double-blind trial. Br J Psychiatry. 1987; 150:685-689.
44. Luchins DJ, Dojka D. Lithium and propranolol in aggression and self-injurious behavior in the mentally retarded. Psychopharmacol Bull. 1989; 25:372-375.
45. Haas JF, Cope DN. Neuropharmacologic management of behavior sequelae in head injury: a case report. Arch Phys Med Rehabil. 1985; 66:472-474.
46. Hornstein A, Seliger G. Cognitive side effects of lithium in closed head injury. J Neuropsychiatry. 1989; 1:446-447. Letter.
47. Sheard MH. Effect of lithium on human aggression. Nature. 1971; 230:113-114.
48. Tupin JP, Smith DB, Clanon TL, et al. The long-term use of lithium in aggressive prisoners. Compr Psychiatry. 1973; 14:311-317.
49. Sheard MH, Marini JL, Bridges CI, et al. The effect of lithium on impulsive aggressive behavior in man. Am J Psychiatry. 1976; 133:1409-1413.
50. Schiff HB, Sabin TD, Geller A, et al. Lithium in aggressive behavior. Am J Psychiatry. 1982; 139:1346-1348.
51. Hakola HP, Laulumaa VA. Carbamazepine in treatment of violent schizophrenics. Lancet. 1982; 1:1358. Letter.
52. Luchins DJ. Carbamazepine in violent non-epileptic schizophrenics. Psychopharmacol Bull. 1984; 20:569-571.
53. Mattes JA. Carbamazepine for uncontrolled rage outbursts. Lancet. 1984; 2:1164-1165. Letter.
54. Okuma T, Yamashita I, Takahashi R, et al. A double-blind study of adjunctive carbamazepine versus placebo on excited states of schizophrenic and schizoaffective disorders. Acta Psychiatr Scand. 1989; 80:250-259.
55. Neppe VM. Carbamazepine as adjunctive treatment in nonepileptic chronic inpatients with EEG temporal lobe abnormalities. J Clin Psychiatry. 1983; 44:326-331.
56. Neppe VM. Carbamazepine in nonresponsive psychosis. J Clin Psychiatry. 1988; 49(suppl):22-28.
57. Simhandl C, Meszaros K. The use of carbamazepine in the treatment of schizophrenic and schizoaffective psychoses: a review. J Psychiatry Clin Neurosci. 1992; 17:1-14.
58. Young JL, Hillbrand M. Carbamazepine lowers aggression: a review. Bull Am Acad Psychiatry Law. 1994; 22:53-61.
59. Wassef A, Watson D, Morrison P, Bryant S, Flack J. Neuroleptic-valproic acid combination in treatment of psychotic symptoms: a three-case report. J Clin Psychopharmacol. 1989; 9:45-48.
60. Morinigo A, Martin J, Gonzalez S, Mateo I. Treatment of resistant schizophrenia with valproate and neuroleptic drugs. J Clin Psychiatry. 1989; 11:199-207.
61. Alam MY, Klass DB, Luchins DJ, Aleem Y, Enich G. Effectiveness of divalproex sodium, valproic acid and carbamazepine in aggression (poster). NCDEU 35th Annual Meeting; Orlando, Fla; 1995.
62. Wilcox J. Divalproex sodium in the treatment of aggressive behavior. Ann Clin Psychiatry. 1994; 6:17-20.
63. Keats MM, Mukherjee S. Antiaggressive effect of adjunctive clonazepam in schizophrenia associated with seizure disorder. J Clin Psychiatry. 1988; 49:117-118.
64. Karson CN, Weinberger DR, Bigelow L, Wyatt RJ. Clonazepam treatment of chronic schizophrenia: negative results in a double-blind, placebo-controlled trial. Am J Psychiatry. 1982; 139:1627-1628.
65. Jackson RD, Corrigan JD, Arnett JA. Amitriptyline for agitation in head injury. Arch Phys Med Rehabil. 1985; 66:180-181.
66. Mysiw WJ, Jackson RD, Corrigan JD. Amitriptyline for post-traumatic agitation. Am J Phys Med Rehabil. 1988; 67:29-33.
67. Simpson DM, Foster D. Improvement in organically disturbed behavior with trazodone treatment. J Clin Psychiatry. 1986; 47:191-193.
68. Pinner E, Rich CL. Effects of trazodone on aggressive behavior in seven patients with organic mental disorders. Am J Psychiatry. 1988; 145:1295-1296.
69. O'Neil M, Page N, Adkins WN, et al. Tryptophantrazodone treatment of aggressive behavior. Lancet. 1986; 2:859-860. Letter.
70. Greenwald BS, Marin DB, Silverman SM. Serotonergic treatment of screaming and banging in dementia. Lancet. 1986; 2:1464-1465. Letter.
71. Wilcock GK, Stevens J, Perkins A. Trazodone/tryptophan for aggressive behavior. Lancet. 1987; 1:929-930. Letter.
72. Gedye A. Serotonergic treatment for aggression in a Down's syndrome adult showing signs of Alzheimer's disease. Journal of Mental Deficiency Research. 1991; 35:247-258.
73. Coccaro EF, Astill JL, Herbert JL, et al. Fluoxetine treatment of impulsive aggression in DSM-III-R personality disorder patients. J Clin Psychopharmacol. 1990; 10:373-375. Letter.
74. Goldman MB, Janecek HM. Adjunctive fluoxetine improves global function in chronic schizophrenia. J Neuropsychiatr Clin Neurosci. 1990; 2:429-431.
75. Fava M, Rosenbaum JF, Pava JA, et al. Anger attacks in unipolar depression, part 1: clinical correlates and response to fluoxetine treatment. Am J Psychiatry. 1993; 150:1158-1163.
76. Markowitz PI. Effect of fluoxetine on self-injurious behavior in the developmentally disabled: a preliminary study. J Clin Psychopharmacol. 1992; 12:27-31.
77. Cornelius JR, Soloff PH, Perel JM, Ulrich RF. Fluoxetine trial in borderline personality disorder. Psychopharmacol Bull. 1990; 26:151-154.
78. Cornelius JR, Soloff PH, Perel JM, Ulrich RF. A preliminary trial of fluoxetine in refractory borderline patients. J Clin Psychopharmacol. 1991; 11:116-120.
79. Burton TM. Medical flap: anti-depression drug of Eli Lilly loses sales after attack by sect. Wall Street Journal. Friday, April 19, 1991.
80. Grinfeld MJ. Jury finds Prozac did not cause violence. Psychiatric Times. February 1995:33.
81. Teicher MH, Glod C, Cole JO. Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry. 1990; 147:207-210.
82. Troisi A, Vicario E, Nuccetelli F, Ciani N, Pasini A. Effects of fluoxetine on aggressive behavior of adult inpatients with mental retardation and epilepsy. Pharmacopsychiatry. 1995; 28:73-76.
83. Beasley CM, Potvin JH, Masica DN, Wheadon DE, Dornseif BE, Genduso LA. Fluoxetine: no association with suicidality in obsessive-compulsive disorder. J Affect Disord. 1992; 24:1-10.
84. Tollefson GD, Rampey AH, Beasley CM, Enas GG, Potvin JH. Absence of a relationship between adverse events and suicidality during pharmacotherapy for depression. J Clin Psychopharmacol. 1994; 14:163-169.
85. Heilgenstein JH, Beasley CM, Potvin JH. Fluoxetine not associated with increased aggression in controlled clinical trials. Int Clin Psychopharmacol. 1993; 8:277-280.
86. Mann JJ, Kapur S. The emergence of suicidal ideation and behavior during antidepressant pharmacotherapy. Arch Gen Psychiatry. 1991; 48:1027-1033.
87. Ratey JJ, Sovner R, Mikkelsen E, et al. Buspirone therapy for maladaptive behavior and anxiety in developmentally disabled persons. J Clin Psychiatry. 1989; 50:382-384.
88. Ratey J, Sovner R, Parks A, et al. Buspirone treatment of aggression and anxiety in mentally retarded patients: a multiple-baseline, placebo lead-in study. J Clin Psychiatry. 1991; 52:159-162.
89. Gedye A. Buspirone alone or with serotonergic diet reduced aggression in a developmentally disabled adult. Biol Psychiatry. 1991; 30:88-91.
90. Quiason N, Ward D, Kitchen T. Buspirone for aggression. J Am Acad Child Adolesc Psychiatry. 1991; 30:1026. Letter.
91. Levine AM. Buspirone and agitation in head injury. Brain Inj. 1988; 2:165-167.
92. Bioulac B, Benezech M, Renaud B, et al. Serotonergic dysfunction in the 47,XYY syndrome. Biol Psychiatry. 1980; 15:917-923.
93. Morand C, Young SN, Ervin FR. Clinical response of aggressive schizophrenics to oral tryptophan. Biol Psychiatry. 1983; 18:575-578.
94. Volavka J, Crowner M, Brizer D, et al. Tryptophan treatment of aggressive psychiatric inpatients. Biol Psychiatry. 1990; 28:728-732.
95. Vartiainen H, Tiihonen J, Putkonen A, Virkkunen M, Hakola P, Lehto H. Citalopram, a selective serotonin reuptake inhibitor, in the treatment of aggression in schizophrenia. Acta Psychiatr Scand. 1995; 91:348-351.
96. Rasmussen DL, Olivier B, Raghoebar M, Mos J. Possible clinical applications of serenics and some implications of their preclinical profile for their clinical use in psychiatric disorders. Drug Metabolism Drug Interactions. 1990; 8:159-186.
97. Tiihonen J, Hakola P, Paanila J, Turtiainen M. Eltoprazine for aggression in schizophrenia and mental retardation. Lancet. 1993; 341:307.